Columbus Publishers

International Journal of Surgery and Reports

Volume 02: Issue 01

Butman J, et al.

JB participated in patient’s care during his surgery clerkship and wrote the introduction, case presentation, discussion, and conclusion for the manuscript. JB also assisted with literature review. JRO is the surgical oncologist who performed the procedure and provided guidance and suggested edits throughout the writing of the manuscript. JAB performed the literature review and assisted in editing the manuscript.

## Acknowledgements

Not applicable.

References

- 1. Yao JC, Hassan M, Phan A, et al. (2008) One hundred years after “Carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26: 30633- 3072.
- 2. Dasari A, Shen C, Halperin D, et al. (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3: 1335-1342.
- 3. American Cancer Society. Pancreatic neuroendocrine tumor. Cancer.org.
- 4. Ro C, Chai W, Yu VE, et al. (2013) Pancreatic neuroendocrine tumors: biology, diagnosis, and treatment. Chin J Cancer 32:312-324.
- 5. Brooks JC, Shavelle RM, Vavra-Musser KN (2019) Life expectancy in pancreatic neuroendocrine cancer. Clin Res Hepatol Gastroenterol 43: 88-97.
- 6. Clancy TE (2016) Surgical management of pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am 30: 103‐118.
- 7. Cherif R, Gaujoux S, Couvelard A, et al. (2012) Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J Gastrointest Surg 16: 2045-2055.
- 8. Jeune F, Taibi A, Gaujoux S (2020) Update on the Surgical Treatment of Pancreatic Neuroendocrine Tumors. Scand J Surg 109: 42-52.
- 9. Kourounis G, Paul Tabet P, Moris D, et al. (2017) Irreversible electroporation (Nanoknife® treatment) in the field of hepatobiliary surgery: Current status and future perspectives. J BUON 22: 141-149.
- 10. Ahmed M, Brace CL, Lee FT Jr, et al. (2011) Principles of and advances in percutaneous ablation. Radiology 258: 351-369.
- 11. Jourabchi N, Beroukhim K, Tafti BA, et al. (2014) Irreversible electroporation (NanoKnife) in cancer treatment. Gastrointestinal Intervention 3: 8-18.
- 12. Savic LJ, Chapiro J, Hamm B, et al. (2016) Irreversible electroporation in interventional oncology: Where we stand and where we go. Rofo 188: 735-745. doi:10.1055/s-0042-104203
- 13. Girelli R, Frigerio I, Giardino A, et al. (2013) Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg 398: 63-69.
- 14. Pillai K, Akhter J, Chua TC, et al. (2015) Heat sink effect on tumor ablation characteristics as observed in monopolar radiofrequency, bipolar radiofrequency, and microwave, using ex vivo calf liver model. Medicine (Baltimore) 94: e580.
- 15. Goldberg SN, Hahn PF, Tanabe KK, et al. (1998) Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 9: 101-111.
- 16. Narayanan G (2015) Irreversible Electroporation. Semin Intervent Radiol 32: 349-355.
- 17. De Wilde RF, Besselink MGH, van der Tweel I, et al. (2012) Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 99: 404-410.
- 18. Pastrana Del Valle J, Mahvi DA, Fairweather M, et al. (2021) The improvement in post-operative mortality following pancreaticoduodenectomy between 2006 and 2016 is associated with an improvement in the ability to rescue patients after major morbidity, not in the rate of major morbidity. HPB (Oxford) 23: 434-443.
- 19. Mirrielees JA, Weber SM, Abbott DE, et al. (2020) Scarborough JE. Pancreatic fistula and delayed gastric emptying are the highest-impact complications after whipple. J Surg Res 250: 80-87.
- 20.
- Long-term endocrine and exocrine insufficiency after
- 21.
- for the treatment of pancreatic
- 22.
- advanced pancreatic